Company Profile

SIMCERE PHARMA

2096 Drug Manufacturers - Specialty & Generic
Description

Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. The company focusses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its principal products include Sanbexin, an edaravone and dexborneol concentrated solution for injection; Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; COSELA, a trilaciclib hydrochloride for injection; Iremod, an iguratimod tablet; and XIANNUOXIN, a simnotrelvir tablets/ritonavir tablets. The company also offers promotion services for pharmaceutical products. In addition, it engages in the manufacture of pharmaceutical ingredients; and property management business. The company has a strategic regional licensing partnership with Vivoryon Therapeutics N.V. to develop and commercialize SIM0801 and other drugs in the Greater China region; and license and collaboration agreement with Guangzhou Fermion Technology Co., Ltd. to develop FZ002-037, an oral SSTR4 agonist for pain treatment. Simcere Pharmaceutical Group Limited was founded in 1995 and is headquartered in Nanjing, China.

Reports

This company has 5 ESG reports available.

ESG Performance Overview

Select a KPI indicator to view performance trend

KPI Indicators

A1.1 Emission Types and Data
36 Data Points
Indicator Data Points Actions
SOₓ Emissions 12
NOₓ Emissions 12
Airborne Particulate Matter (PM) Emissions 12
A1.2 Direct (Scope 1) and Indirect (Scope 2) GHG Emissions
48 Data Points
Indicator Data Points Actions
Total GHG Emissions Intensity (By Revenue) 12
Total GHG Emissions 12
Direct GHG Emissions (Scope 1) 12
Indirect Energy Emissions (Scope 2) 12
A1.3 Hazardous Waste
24 Data Points
Indicator Data Points Actions
Total Hazardous Waste Intensity (By Revenue) 12
Total Hazardous Waste 12
A1.4 Non-Hazardous Waste
22 Data Points
Indicator Data Points Actions
Non-Hazardous Waste Disposed 10
Total Non-Hazardous Waste Intensity (By Revenue) 12
A1.5 Emission Targets
1 Data Points
Indicator Data Points Actions
Target Reduction in GHG Intensity Percentage by 2030 Compared to 2020 1

A2.1 Energy Consumption
107 Data Points
Indicator Data Points Actions
Energy Consumption Intensity (By Revenue) 1
Comprehensive Energy Consumption Intensity (By Revenue) 11
Total Energy Consumption 12
Gasoline Consumption 12
Diesel Fuel Consumption 12
Natural Gas Consumption 12
LPG Consumption 9
Renewable Energy Consumption 11
Wind Energy 2
Solar Energy 1
Purchased Electricity 12
Purchased Steam 12
A2.2 Water Consumption
48 Data Points
Indicator Data Points Actions
Total Water Withdrawal 3
Total Wastewater Discharge 12
Water Consumption 12
Water Consumption Intensity (By Revenue) 12
Wastewater Discharge Intensity 9
A2.3 Energy Use Efficiency Targets
3 Data Points
Indicator Data Points Actions
Investment in Energy-saving and Emission-reduction Technology Transformation 1
Target Energy Consumption Reduction Percentage Compared to Last Year 1
Target Electricity Usage Reduction Percentage Compared to Last Year 1
A2.4 Water Efficiency Targets
1 Data Points
Indicator Data Points Actions
Target Water Consumption Reduction Percentage Compared to Last Year 1
A2.5 Total Packaging Material Used
5 Data Points
Indicator Data Points Actions
Packaging Materials Consumed 3
Packaging Material Intensity (By Revenue) 2

B1.1 Amount and Distribution of Workforce
68 Data Points
Indicator Data Points Actions
Number of Total Employees 5
Number of Male Employees 5
Number of Female Employees 5
Percentage of Male Employees 2
Percentage of Female Employees 5
Number of Full-time Employees 3
Number of Employees Aged Below 30 5
Number of Employees Aged 30-50 5
Number of Employees Aged Above 50 5
Percentage of Employees Aged Below 30 1
Percentage of Employees Aged 30-50 1
Percentage of Employees Aged Above 50 1
Number of Employees in Mainland China 5
Number of Employees in Overseas 5
Percentage of Employees in Mainland China 1
Percentage of Employees in Overseas 1
Number of Master's Degree Employees 1
Number of Doctoral Degree Employees 1
Percentage of Master's Degree Employees 1
Percentage of Doctoral Degree Employees 1
Number of Senior Management Employees 2
Number of Middle Management Employees 2
Number of General Employees 2
Percentage of Senior Management Employees 1
Percentage of Middle Management Employees 1
Percentage of General Employees 1
B1.2 Employee Turnover Rate
29 Data Points
Indicator Data Points Actions
Turnover Rate of Female Employees 4
Turnover Rate of Male Employees 4
Turnover Rate of Employees Aged Below 30 4
Turnover Rate of Employees Aged 30-50 4
Turnover Rate of Employees Aged Above 50 4
Turnover Rate of Employees in Mainland China 4
Turnover Rate of Total Employees 2
Turnover Rate of Employees in Overseas 3

B2.1 Number and Rate of Work-related Fatalities
3 Data Points
Indicator Data Points Actions
Number of Work-related Fatalities 3

B3.1 The Percentage of Employees Trained
18 Data Points
Indicator Data Points Actions
Percentage of Employees Trained 3
Percentage of Trained Male Employees 3
Percentage of Trained Female Employees 3
Percentage of Trained Senior Management 3
Percentage of Trained Middle Management 3
Percentage of Trained General Employees 3
B3.2 Average Training Hours Completed per Employee
17 Data Points
Indicator Data Points Actions
Average Training Hours per Employee 1
Average Training Hours (Male) 3
Average Training Hours (Female) 3
Average Training Hours (Senior Management) 3
Average Training Hours (Middle Management) 3
Average Training Hours (General Staff) 3
Average Training Hours (R&D Personnel Employees) 1

B5.1 Number of Suppliers by Geographical Region
3 Data Points
Indicator Data Points Actions
Number of Total Suppliers 2
Number of Suppliers in Mainland China 1

B6.3 Protection on Intellectual Property Rights
21 Data Points
Indicator Data Points Actions
Number of Intellectual Property Rights Obtained by the Company 3
Number of Patents Applied 3
Number of Patents Granted 3
Number of Patents Held 1
Number of Invention Patents 1
Number of New Patent Applications 2
Number of Trademark Applications 2
Number of Trademark Registrations 2
Accumulative Number of Patent Applications 1
Accumulative Number of Patents Granted 2
Number of Authorised Utility Model Patents 1
B6.4 Quality Assurance Process and Recall Procedures
2 Data Points
Indicator Data Points Actions
Passing Rate of Third-party Accreditation Performed under the Quality Management System 2

B7.1 Confirmed Incidents of Corruption
1 Data Points
Indicator Data Points Actions
Number of Concluded Corruption Lawsuits 1
B7.3 Anti-corruption Training
2 Data Points
Indicator Data Points Actions
Average Anti-corruption Training Hours for Directors and Management 1
Total Hours of Anti-corruption Training for Employees 1

B8.2 Resources Contributed to the Community
10 Data Points
Indicator Data Points Actions
Total Social Investment 3
Investment in Education Donation 1
Total Public Welfare Donations 2
Donations to Disaster Relief Contributions to Public Welfare 2
Total In-kind Donations 2

General
1 Data Points
Indicator Data Points Actions
Target Reduction in GHG Intensity Percentage by 2025 Compared to 2020 1